In a novel deal, U.K. CRO Ergomed has hitched up with Cel-Sci ($CVM) for a Phase III trial of its head and neck cancer drug, but instead of just handling the study, Ergomed is putting up $30 million to fund development in exchange for single-digit royalties from the treatment. Neither company disclosed further financial details. More